# US 10,478,475 B2 · Use of von Willebrand factor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,478,475 B2
- Document ID: US10478475B2
- Status: Granted
- Kind: B2
- Application number: 15/564,783
- Filed: 2016-04-06
- Published: 2018-04-26
- Granted: 2019-11-19
- Earliest claimed: 2015-04-07
- Assignees: Laboratoire Francais Du Fractionnement Et Des Biotechnologies; CTRE Hospitalier Universitaire de Lille; Universite Lille 2 Droit Et Sante
- Applicants: Laboratoire Francais du Fractionnement et des Biotechnologies; CTRE Hospitalier Universitaire de Lille; Universite Lille 2 Droit et Sante
- Inventors: Sophie Susen; Andre Vincentelli; Eric Van Belle; Antoine Rauch; Flavien Vincent
- Web page: https://patentgrep.com/patent/US10478475B2

## CPC

- A61K 38/36: Blood coagulation or fibrinolysis factors
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/37: Factors VIII
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a von Willebrand factor composition for the prevention and/or the treatment of haemorrhage and/or bleeding in patients with mechanical circulatory support.

## Claims

### Claim 1

A method of treating or preventing haemorrhage and/or bleeding in patients with mechanical circulatory support, comprising administering to the patient a pharmaceutical composition comprising von Willebrand factor in an amount effective for treating or preventing haemorrhage and/or bleeding in patients with mechanical circulatory support, wherein the composition contains a residual amount of factor VIII less than or equal to 10 IU/100 IU VWF:RCo, and wherein the composition is administered to the patient at a dose of 45 IU/kg to 55 IU/kg of body weight.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the dose is 50 IU/kg of body weight.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the dose is administered repeatedly at a rate of two administrations per week.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition is first administered four to seven days after the mechanical circulatory support is introduced into the patient.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the composition is administered intravenously.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the composition is depleted of factor VIII.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the composition is depleted of ADAMTS 13.

### Claim 8 (depends on 1)

The method according to claim 1, wherein high-molecular weight multimers represent at least 65% of total multimer content of von Willebrand factor contained in the pharmaceutical composition.

### Claim 9 (depends on 1)

The method according to claim 1, wherein high-molecular weight multimers represent at least 70% of total multimer content of von Willebrand factor contained in the pharmaceutical composition.

### Claim 10 (depends on 1)

The method according to claim 1, wherein high-molecular weight multimers represent at least 75% of total multimer content of von Willebrand factor contained in the pharmaceutical composition.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the content of high-molecular weight multimers is close to that of plasma.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the high-molecular weight multimers are present in amounts sufficient for vivo activity.